Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

ClinicalTrials.gov ID: NCT01730833

Public ClinicalTrials.gov record NCT01730833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer

Study identification

NCT ID
NCT01730833
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
City of Hope Medical Center
Other
Enrollment
63 participants

Conditions and interventions

Interventions

  • pertuzumab Biological
  • trastuzumab Biological
  • paclitaxel albumin-stabilized nanoparticle formulation Drug
  • laboratory biomarker analysis Other

Biological · Drug · Other

Eligibility (public fields only)

Age range
19 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 16, 2013
Primary completion
Jan 11, 2021
Completion
Apr 19, 2026
Last update posted
Jun 15, 2026

2013 – 2026

United States locations

U.S. sites
3
U.S. states
1
U.S. cities
3
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010
City of Hope Antelope Valley Lancaster California 93534
City of Hope- South Pasadena Cancer Center South Pasadena California 91030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01730833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01730833 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →